Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01981850 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Study of RO7490677 In Participants With Myelofibrosis
A Phase 2 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 2
- Development phase
- 125
- Enrollment target
NCT01981850 is a Phase 2 study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 125 participants.
The verdict
NCT01981850, a Phase 2 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 125 participants
- Enrollment target
Study Summary
RO7490677 is an investigational drug that is being developed for possible use in the treatment of myelofibrosis (MF), a disease in which the bone marrow, which is the organ in the body that makes blood cells, is replaced by fibrosis, or excess scar tissue. The purpose of this study is to gather information on whether RO7490677 has an effect on the MF disease, whether it is safe in patients with MF, and how well it is tolerated.
Interventions
- DRUG Ruxolitinib
- BIOLOGICAL RO7490677
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 125 participants |
| Start Date | 2013-10-01 |
| Est. Completion | 2020-07-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01981850
The ClinicalTrials.gov registry entry for NCT01981850 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 125 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ruxolitinib is the first listed.
NCT01981850 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01981850 about?
NCT01981850 is a clinical study titled "A Phase 2 Study of RO7490677 In Participants With Myelofibrosis". RO7490677 is an investigational drug that is being developed for possible use in the treatment of myelofibrosis (MF), a disease in which the bone marrow, which is the organ in the body that makes blood cells, is replaced by fibrosis, or excess scar tissue. The purpose of this study is to gather inf...
What is the current status of trial NCT01981850?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 125 participants. The study started on 2013-10-01. Estimated completion is 2020-07-10.
What interventions are being tested in trial NCT01981850?
The interventions under investigation include: Ruxolitinib (DRUG), RO7490677 (BIOLOGICAL).
Who is sponsoring clinical trial NCT01981850?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.